Menu

Elutia Inc. ELUT

Full chart Compare
Set alert

Price alert · ELUT

All alert types
0.75 USD 0.00 (+0.00%)

At closeNov 5, 2026, 4:00 PM EST

0.75 0.00 0.00%

After hours · Nov 5, 4:00 PM ET

Day range unavailable

0.50 52-week range 1.39
YTD
+8.35%
1 year
-21.78%
Market cap
33.26M
Revenue (ttm)
24.99M
Profit margin
-261.08%
EPS (ttm)
-0.64
Shares out
30.25M
Forward P/E
-3.98
YTD return
+8.35%
1-year return
-21.78%
Avg volume
180.76K
Previous close
0.7509
52-week range
0.50 – 1.39
Beta
0.76
Price target
9.00 (+1098.6%)
Earnings date
Aug 7, 2024

2Y -2.9390 (-79.65%)

2.00004.0000Nov 24Feb 25Apr 25Jun 25Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26Oct 260.7510

Key statistics

Enterprise value
125.88M
PEG ratio
0.00
Price / sales
6.06
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-0.90%
Free cash flow
490.13K
Total cash
18.19M
Total debt
22.81M
Return on equity
0.00%
Short % of float
0.54%
50-day average
3.86
200-day average
3.63

Financials — quick view

All financials
ELUT Revenue — quarterly 2.43M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ELUT Net income — quarterly -7.65M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ELUT EPS — quarterly -0.17
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ELUT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.33——
Aug 7, 2024Jun 1, 20240.00-1.14——
Aug 7, 2024Jun 1, 20240.00———
May 9, 2024Mar 1, 20240.00———
May 9, 2024Mar 1, 20240.00-0.75——
Mar 7, 2024Dec 1, 20230.00-0.66——

Upgrades / downgrades

ELUT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024Cantor FitzgeraldreitOverweightOverweight
Sep 6, 2024Cantor FitzgeraldreitOverweightOverweight
Aug 8, 2024Cantor FitzgeraldmainOverweightOverweight
Jun 21, 2024Lake StreetmainBuyBuy
Jun 20, 2024Cantor FitzgeraldmainOverweightOverweight
Jun 18, 2024Cantor FitzgeraldmainOverweightOverweight

About Elutia Inc.

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
elutia.com

News

Your note

Sign in to keep a note on ELUT — it syncs with the Stock Master app.

Insider holders

ELUT insider holders
InsiderRelationLatest transactionDateShares held
BIRCHVIEW CAPITAL, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 26, 20230
ENGLESE THOMASOfficerSaleMar 8, 202317,917
FERGUSON MATTHEW BChief Financial OfficerConversion of Exercise of derivative securityDec 9, 2024318,744
HIGHCAPE CAPITAL, L.P.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJul 29, 20240
MILLS CHARLES RANDALChief Executive OfficerConversion of Exercise of derivative securityDec 9, 2024267,298
WILLIAMS MICHELLE LEROUXOfficerConversion of Exercise of derivative securityDec 9, 202468,399

Institution ownership

ELUT institution ownership
Holder% heldSharesValueReported
Nantahala Capital Management, LLC9.47%2,864,94712.55MSep 29, 2024
AIGH Capital Management LLC8.30%2,510,44211.00MSep 29, 2024
SilverArc Capital Management, LLC5.44%1,645,8087.21MSep 29, 2024
Birchview Capital, LP4.37%1,321,2155.79MSep 29, 2024
Knollwood Investment Advisory, LLC3.09%934,6174.09MSep 29, 2024
Perkins Capital Management, Inc.2.83%856,5523.75MSep 29, 2024

Fund ownership

ELUT fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.08%327,3301.43MSep 29, 2024
Vanguard Extended Market Index Fund0.54%163,575716.46KSep 29, 2024
Fidelity Extended Market Index Fund0.33%100,339439.48KOct 30, 2024
World Funds Tr-Perkins Discovery Fund0.13%40,000175.20KSep 29, 2024
North Square Inv Tr-North Square Kennedy MicroCap Fund0.11%34,239149.97KSep 29, 2024
Fidelity Total Market Index Fund0.11%33,074144.86KOct 30, 2024